The Search for an Effective Therapy to Treat Fragile X Syndrome: Dream or Reality?
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
) gene. Multiple roles have been attributed to this protein, ranging from RNA transport (from the nucleus to the cytoplasm, but also along neurites) to translational control of mRNAs. Over the last 20 years many studies have found a large number of FMRP mRNA targets, but it is still not clear which are those playing a critical role in the etiology of FXS. So far, no therapy for FXS has been found, making the quest for novel targets of considerable importance. Several pharmacological approaches have been attempted, but, despite some promising preclinical results, no strategy gave successful outcomes, due either to the induction of major side effects or to the lack of improvement of the phenotypes. However, these studies suggested that, in order to measure the effectiveness of a specific treatment, trials should be redesigned and new endpoints defined in FXS patients. Nevertheless, the search for new therapeutic targets for FXS is very active. In this context, the advances in animal modeling, coupled with better understanding of neurobiology and physiopathology of FXS, are of crucial importance in developing new selected treatments. Here, we discuss the pathways that were recently linked to the physiopathology of FXS (mGluR, GABAR, insulin, Insulin-like Growth Factor 1 (IGF-1), MPP-9, serotonin, oxytocin and endocannabinoid signaling) and that suggest new approaches to find an effective therapy for this disorder. Our goal with this review article is to summarize some recent relevant findings on FXS treatment strategies in order to have a clearer view of the different pathways analyzed to date emphasizing those shared with other synaptic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 3×
“The mGluR theory regarding the pathophysiology of FXS states that the lack of FMRP hyperactivates the mGluR5mediated pathway leading to the most prominent features of FXS (Bear et al., 2004).”
BackgroundMethodAltered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 1×
“…abnormalities are associated with deregulated synaptic plasticity: in mouse hippocampal mGluR dependent Long Term Depression (LTD) is increased (Huber et al., 2002), while Long Term Potentiation (LTP) is reduced in somatosensory and anterior cingulate cortex (Desai et al., 2006) as well as in…”
BackgroundGiant synaptic potentials in immature rat CA3 hippocampal neurones.
Ben‐Ari, Y., Cherubini, E., Corradetti, R., & Gaiarsa, J. L. (1989) · The Journal of Physiology · doi:10.1113/jphysiol.1989.sp017762 · Cited by 1,317
Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function
Bassell, G. J., & Warren, S. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.004 · Cited by 1,051
Oxytocin-Mediated GABA Inhibition During Delivery Attenuates Autism Pathogenesis in Rodent Offspring
Tyzio, R., Nardou, R., Ferrari, D. C., Tsintsadze, T., Shahrokhi, A., Eftekhari, S., Khalilov, I., Tsintsadze, V., Brouchoud, C., Chazal, G., et al. (2014) · Science · doi:10.1126/science.1247190 · Cited by 601 · cited 2×
“Consistently, blocking oxytocin signaling in naïve mothers resulted in the production of offspring with electrophysiological and behavioral autistic-like features (Tyzio et al., 2014).”
BackgroundAdvances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596
The serotonin system in autism spectrum disorder: From biomarker to animal models
Muller, C. L., Anacker, A. M. J., & Veenstra-VanderWeele, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.010 · Cited by 531 · cited 2×
“Conversely, several mouse models of ASD, such as the 15q11-13 duplication and Smith-LaemliOpitz syndrome models, to which we can also include the Fmr1-KO mouse, display altered 5-HT signaling (Muller et al., 2016).”
BackgroundBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · cited 2×
“neuronal cultures with minocycline (Bilousova et al., 2009).”
BackgroundBerry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328 · cited 1×
“So far, compounds like Acamprosate, Ganaxolone, Arbaclofen and Riluzole have been tested, but, despite the very mild side effects and good tolerability, they have caused very limited improvements in preliminary studies (Berry-Kravis et al., 2012; Erickson et al., 2014a,b; Ligsay et al., 2017).”
BackgroundLeigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., et al. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318287cd17 · Cited by 298 · cited 2×
“Until now, minocycline has been shown to be successful in two different clinical trials (Paribello et al., 2010; Leigh et al., 2013) and, importantly, treatment with mynocline resulted in the improvement of some event-related potentials compared with placebo (Schneider et al., 2013).”
ResultBerry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4109 · Cited by 270
Osterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230 · cited 2×
“On the other side, also reducing the activation of the ERK pathway with lovastatin (a drug that inhibits the Ras-ERK1/2 activation by interfering with Ras recruitment to the membrane) or rimonabant (see endocannabinoid pathway) resulted in an improvement of Fmr1-KO cognition (Busquets-Garcia et al., 2013; Osterweil et…”
BackgroundOpen-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · cited 2×
“Until now, minocycline has been shown to be successful in two different clinical trials (Paribello et al., 2010; Leigh et al., 2013) and, importantly, treatment with mynocline resulted in the improvement of some event-related potentials compared with placebo (Schneider et al., 2013).”
ResultReinhard, S. M., Razak, K., & Ethell, I. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00280 · Cited by 219 · cited 1×
“So far, misregulated activation of this enzyme has been implicated in a number of neurodegenerative disorders, including traumatic brain injury, multiple sclerosis and Alzheimer’s disease but also in neurodevelopmental disorders (Reinhard et al., 2015).”
BackgroundLemonnier, E., Villeneuve, N., Sonie, S., Serret, S., Rosier, A., Roue, M., Brosset, P., Viellard, M., Bernoux, D., Rondeau, S., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.10 · Cited by 218 · cited 1×
“Very recently, the same authors performed a clinical trial and remarkably showed that bumetanide improves the core symptoms of ASD and presents a favorable benefit/risk ratio particularly at 1.0mg twice a day (Lemonnier et al., 2017).”
ResultWang, J., Ethridge, L. E., Mosconi, M. W., White, S. P., Binder, D. K., Pedapati, E. V., Erickson, C. A., Byerly, M. J., & Sweeney, J. A. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9191-z · Cited by 176 · cited 1×
“…concerning blood-based and neurophysiological measures (Ethridge et al., 2016; Ray et al., 2016; AlOlaby et al., 2017; Pellerin et al., 2017; Wang et al., 2017), it would be interesting to develop cell-based biomarkers improving analysis of FXS iPS cell lines, while parameters analyzed so…”
BackgroundFMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts
Castets, M., Schaeffer, C., Bechara, E., Schenck, A., Khandjian, E. W., Luche, S., Moine, H., Rabilloud, T., Mandel, J.-L., & Bardoni, B. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi077 · Cited by 162 · cited 1×
“We can underline that only a few examples of FXS cell lines exist that can be used to investigate preclinical treatment in cellulo or screening with chemical libraries (Castets et al., 2005; Khalfallah et al., 2017).”
BackgroundSelf-citationSidhu, H., Dansie, L. E., Hickmott, P. W., Ethell, D. W., & Ethell, I. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1162-14.2014 · Cited by 155 · cited 1×
“Double KO mice lacked the typical major symptoms of FXS observed in Fmr1-KOs (Sidhu et al., 2014).”
BackgroundEffects of intranasal oxytocin on social anxiety in males with fragile X syndrome
Hall, S. S., Lightbody, A. A., McCarthy, B. E., Parker, K. J., & Reiss, A. L. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.07.020 · Cited by 143 · cited 1×
“Recent studies suggest that intranasal administration of oxytocin can ameliorate some symptoms of FXS, showing anxiolytic and pro-social qualities (Hall et al., 2012).”
BackgroundEarly developmental alterations in GABAergic protein expression in fragile X knockout mice
Adusei, D. C., Pacey, L. K. K., Chen, D., & Hampson, D. R. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.05.002 · Cited by 139
Quiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133 · cited 1×
“A similar new clinical trial was performed in a cohort of 183 FXS using basimglurant, a potent and selective mGluR5-negative allosteric modulator (NAM), already administrated as a treatment of depression (Quiroz et al., 2016).”
MethodFragXis Study Group, Youssef, E. A., Berry-Kravis, E., Czech, C., Hagerman, R. J., Hessl, D., Wong, C. Y., Rabbia, M., Deptula, D., John, A., et al. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.177 · Cited by 133
Metformin as targeted treatment in fragile X syndrome
Dy, A. B. C., Tassone, F., Eldeeb, M., Salcedo‐Arellano, M. J., Tartaglia, N., & Hagerman, R. (2018) · Clinical Genetics · doi:10.1111/cge.13039 · Cited by 124
Greiss Hess, L., Fitzpatrick, S. E., Nguyen, D. V., Chen, Y., Gaul, K. N., Schneider, A., Lemons Chitwood, K., Eldeeb, M. A. A. A., Polussa, J., Hessl, D., et al. (2016) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000000334 · Cited by 122 · cited 1×
“…primary endpoint results, this treatment demonstrated a positive effect on cognition, visual reception score improving social interaction and early expressive language development (Greiss Hess et al., 2016), strongly suggesting serotonin re-uptake as a promising target to improve the FXS phenotype.”
BackgroundA metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model
Davidovic, L., Navratil, V., Bonaccorso, C. M., Catania, M. V., Bardoni, B., & Dumas, M.-E. (2011) · Genome Research · doi:10.1101/gr.116764.110 · Cited by 118
Self-citationGross, C., Chang, C.-W., Kelly, S. M., Bhattacharya, A., McBride, S. M. J., Danielson, S. W., Jiang, M. Q., Chan, C. B., Ye, K., Gibson, J. R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.060 · Cited by 117
Early Postnatal Plasticity in Neocortex of Fmr1 Knockout Mice
Desai, N. S., Casimiro, T. M., Gruber, S. M., & Vanderklish, P. W. (2006) · Journal of Neurophysiology · doi:10.1152/jn.00221.2006 · Cited by 113 · cited 1×
“…Long Term Depression (LTD) is increased (Huber et al., 2002), while Long Term Potentiation (LTP) is reduced in somatosensory and anterior cingulate cortex (Desai et al., 2006) as well as in amygdala (Suvrathan and Chattarji, 2011) and in the CA1 region (Lauterborn et al., 2007; Seese et al., 2012).”
BackgroundFragile X Syndrome: from molecular pathology to therapy
Maurin, T., Zongaro, S., & Bardoni, B. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.01.006 · Cited by 113
Self-citationCYFIP family proteins between autism and intellectual disability: links with Fragile X syndrome
Abekhoukh, S., & Bardoni, B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00081 · Cited by 110 · cited 1×
“…of FMRP are also ion channels, molecular motors and proteins involved in cytoskeleton remodeling pathways (Menon et al., 2004; Bardoni et al., 2006; Davidovic et al., 2007; Abekhoukh and Bardoni, 2014; Maurin et al., 2014, 2015; Ferron, 2016; Abekhoukh et al., 2017; Bienkowski et al., 2017).”
BackgroundSelf-citationImpact of prosocial neuropeptides on human brain function
MEYERLINDENBERG, A. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00436-6 · Cited by 109 · cited 1×
“Some promising studies in animal models (Meyer-Lindenberg, 2008) paved the way for clinical trials focusing on the treatment of impaired social skills in a variety of conditions, including ASD and schizophrenia.”
BackgroundElectrocortical changes associated with minocycline treatment in fragile X syndrome
Schneider, A., Leigh, M. J., Adams, P., Nanakul, R., Chechi, T., Olichney, J., Hagerman, R., & Hessl, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113494105 · Cited by 108
Monyak, R. E., Emerson, D., Schoenfeld, B. P., Zheng, X., Chambers, D. B., Rosenfelt, C., Langer, S., Hinchey, P., Choi, C. H., McDonald, T. V., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.51 · Cited by 100 · cited 1×
“Administration of metformin, an FDA-approved anti-diabetic drug, to dFMR1-KO flies (Viollet et al., 2012), leads to an amelioration of memory defects (Monyak et al., 2017).”
BackgroundScotto-Lomassese, S., Nissant, A., Mota, T., Néant-Féry, M., Oostra, B. A., Greer, C. A., Lledo, P.-M., Trembleau, A., & Caillé, I. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5514-10.2011 · Cited by 80
NNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for fragile X syndrome
Deacon, R. M. J., Glass, L., Snape, M., Hurley, M. J., Altimiras, F. J., Biekofsky, R. R., & Cogram, P. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8341-2 · Cited by 78 · cited 2×
“At the microscopic level, abnormal dendritic spine density was rescued (Deacon et al., 2015).”
BackgroundGross, C., Raj, N., Molinaro, G., Allen, A. G., Whyte, A. J., Gibson, J. R., Huber, K. M., Gourley, S. L., & Bassell, G. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.065 · Cited by 71
Gross, C., & Bassell, G. J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00012 · Cited by 63
Abekhoukh, S., Sahin, H. B., Grossi, M., Zongaro, S., Maurin, T., Madrigal, I., Kazue-Sugioka, D., Raas-Rothschild, A., Doulazmi, M., Carrera, P., et al. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.025809 · Cited by 59 · cited 1×
“…of FMRP are also ion channels, molecular motors and proteins involved in cytoskeleton remodeling pathways (Menon et al., 2004; Bardoni et al., 2006; Davidovic et al., 2007; Abekhoukh and Bardoni, 2014; Maurin et al., 2014, 2015; Ferron, 2016; Abekhoukh et al., 2017; Bienkowski et al., 2017).”
BackgroundSelf-citationRett syndrome and the urge of novel approaches to study MeCP2 functions and mechanisms of action
Bedogni, F., Rossi, R. L., Galli, F., Cobolli Gigli, C., Gandaglia, A., Kilstrup-Nielsen, C., & Landsberger, N. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.01.011 · Cited by 51
Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors
Imbesi, M., Uz, T., Manev, R., Sharma, R. P., & Manev, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.10.006 · Cited by 34 · cited 1×
“This drug is an FDA-approved broad-spectrum antibiotic that shows two major effects: (1) it increases the phosphorylation of GluR1; (2) it promotes the membrane insertion of AMPA receptors (Imbesi et al., 2008).”
Background
Cited by
MMPs in learning and memory and neuropsychiatric disorders
Beroun, A., Mitra, S., Michaluk, P., Pijet, B., Stefaniuk, M., & Kaczmarek, L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03180-8 · Cited by 207
Metformin for treatment of fragile X syndrome and other neurological disorders
Gantois, I., Popic, J., Khoutorsky, A., & Sonenberg, N. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-081117-041238 · Cited by 87
FMRP and CYFIP1 at the Synapse and Their Role in Psychiatric Vulnerability
Clifton, N. E., Thomas, K. L., Wilkinson, L. S., Hall, J., & Trent, S. (2020) · Complex Psychiatry · doi:10.1159/000506858 · Cited by 28
Metadata
- Authors
- Castagnola, S., Bardoni, B., & Maurin, T.
- Venue
- Frontiers in Synaptic Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-11-06
- Volume
- 9
- Pages
- 15-15
- ISSN
- 1663-3563 (ISSN-L)
- OpenAlex
- W2766584836
- Cited by
- 40
- References
- 40
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.